|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. B
|
||||||||||||||||
 |
 |
Page 59 |
 |
 |
 |
|
| ||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 59
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
B
Workshop on Venture Philanthropy Strategies Used by Patient Organizations to Support Translational Research
October 3, 2008
Beckman Center
Irvine, CA
Meeting Goals
Convene a group of key stakeholders and experts representing a variety of patient organizations involved in venture philanthropy-supported translational research to identify and discuss best practices used that may improve efficiency and effectiveness. Areas that will be discussed include
criteria used to determine whether there is sufficient evidence to justify moving into translational research—both translational research from basic to clinical and from clinical research toward practice recommendations for the development of a novel drug and/or biomarker/diagnostic;
organizational structure, financial models, legal issues;
partnerships, data sharing, and IP; and
communication strategies.
Workshop Scenario
Session specific scenarios were developed to help guide remarks and frame the discussions and goals for the workshop. At the heart is a hypothetical patient organization, the Colten Foundation. An individual from this foundation is seeking advice on establishing a translational research program for the development of a novel drug and/or biomarker/diagnostic. The foundation is
OCR for page 60
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
trying to plan for and think about the challenges they may encounter and is interested to learn more about how your organization tackled them (where applicable); other best practices, general advice, and lessons learned would also be extremely helpful.
To the best of your knowledge there is no resource currently available that provides advice or “best practices,” so it is important that you convey the most critical information that can assist the foundation with its series of decision matrices. The following questions help frame the context:
What advice would you want to provide to this individual and his or her organization?
What do you wish you had known then that you know now?
If I had only known X, I could have avoided Y.
8:30
Welcome Introductions and Workshop Objectives
TIMOTHY COETZEE, Chair
Executive Director
Fast Forward of the National Multiple Sclerosis Society
8:40
Opening Remarks: Opportunities for Foundation Support
JOYCE NELSON
President and Chief Executive Officer
National Multiple Sclerosis Society
9:05
Challenges and Opportunities for Neurological and Mental Health Translational Research: Basic to Clinical Research and Clinical Toward Practice
DENNIS CHOI
Executive Director, Strategic Neurosciences Initiative
Executive Director, Comprehensive Neurosciences Initiative
Emory University
OCR for page 61
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
SESSION I:
PREPARING FOR A TRANSLATIONAL RESEARCH PROGRAM
Session Objective: Discuss the challenges and issues in the development of a translational research program for the development of either a novel drug or biomarker.
Session I
Scenario
An individual from the Colten Foundation, a patient organization that has sufficient resources, has left you a voice mail asking for advice about how they should go about establishing and maintaining a productive and efficient translational research program. They are particularly interested in the criteria considered and the decision matrix you and your organization used to determine whether or not your organization would establish a formal translational research program for the development of a novel drug and/or biomarker/diagnostic.
9:20
Introduction to the Session
MARIA CARRILLO, Session Chair
Director, Medical and Scientific Relations
Alzheimer’s Association
9:25
Panelist Remarks
RICHARD INSEL
Executive Vice President, Research
Juvenile Diabetes Research Foundation
KATIE HOOD
President and Chief Executive Officer
The Michael J. Fox Foundation for Parkinson’s Research
CELIA DOMINGUEZ
Vice President, Chemistry
CHDI Management, Inc.
OCR for page 62
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
10:05
Respondent Panel Discussion
LOUIS DEGENNARO
Chief Scientific Officer
Leukemia & Lymphoma Society
CYNTHIA JOYCE
Executive Director
Spinal Muscular Atrophy Foundation
LUCIE BRUIJN
Vice President of Research
Amyotrophic Lateral Sclerosis Association
10:20
Discussion with Attendees
MARIA CARRILLO, Moderator
Director, Medical and Scientific Relations
Alzheimer’s Association
10:40
BREAK
SESSION II:
ORGANIZATIONAL STRUCTURE, LEADERSHIP, AND FINANCIAL MODELS
Session Objective: Explore several elements of how a program should be organized to ensure appropriate expertise and leadership is available. Examine a variety of organizational and financial models that may provide optimal support of translational research programs.
Session II
Scenario
The individual from the Colten Foundation who previously spoke to you has used your decision matrix and decided to move ahead with a formal research program. Given how helpful you originally were, they are now asking for more information. In particular they are interested in hearing about models of
OCR for page 63
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
organizational and leadership structure and various financial models that you have found to be effective and efficient.
10:55
Introduction to the Session
TIMOTHY COETZEE, Session Chair
Executive Director
Fast Forward of the National Multiple Sclerosis Society
11:00
Panelist Remarks
JONATHAN SIMONS
President and Chief Executive Officer
Prostate Cancer Foundation
CYNTHIA JOYCE
Executive Director
Spinal Muscular Atrophy Foundation
11:40
Respondent Panel Discussion
JONATHAN JACOBY
Chief Operating Officer
CollabRx, Inc.
LINDA VAN ELDIK
Professor, Department of Cell and Molecular Biology
Northwestern University Feinberg School of Medicine
11:50
Discussion with Attendees
TIMOTHY COETZEE, Moderator
Executive Director
Fast Forward of the National Multiple Sclerosis Society
12:15
LUNCH
OCR for page 64
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
SESSION III:
LEGAL, ACCOUNTING, AND PROCESS ISSUES
Session Objective: Explore the challenges and opportunities in legal, accounting, and associated process issues that a foundation would need to consider in conducting venture philanthropy translational research programs.
Session III
Scenario
You are now very popular with the Colten Foundation! They just sat down with their start-up team and are trying to think about some of the new challenges they may face in terms of appropriate accounting and legal practices, and other process-related issues. They have once again called you to learn more about how you and your organization have navigated these issues.
1:00
Introduction to the Session
TIMOTHY COETZEE, Session Chair
Executive Director
Fast Forward of the National Multiple Sclerosis Society
1:05
Panelist Remarks
ANDREA TOBIAS
Portfolio Advisor
Fast Forward, LLC
KENNETH SCHANER
General Counsel
Kenneth Schaner, PC
PETER HEINECKE
Chief Business Officer
Experimed Bioscience, Inc.
OCR for page 65
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
1:45
Respondent Panel Discussion
CAROL MIMURA
Assistant Vice Chancellor
Intellectual Property & Industry Research Alliances
University of California, Berkeley
JENNIFER TAYLOR
Associate Director, Program Management
Head of External Alliances
Genomics Institute of the Novartis Research Foundation
1:55
Discussion with Attendees
TIMOTHY COETZEE, Moderator
Executive Director
Fast Forward of the National Multiple Sclerosis Society
SESSION IV:
PARTNERSHIPS, DATA SHARING, AND IP
Session Objective: Examine a variety of strategies for partnering with nonprofit organizations, the NIH, and industry. Discuss what policies have been effective in facilitating the efficient management of data sharing and IP.
Session IV
Scenario
The Colten Foundation has previously been working with just a couple of other researchers or companies, but realizes that in order to develop an effective research program they will need to expand their portfolio of collaborators (e.g., nonprofit organizations, the NIH, therapeutic/diagnostic industry). Of course, this results in more questions than answers, especially around issues of data sharing and IP. They again turn to you to help answer their questions. Are there any common resources available? What are some challenges they may encounter, and how your organization tackled them? How and when should strategic collaborations be established or expanded?
OCR for page 66
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
2:10
Introduction to the Session
JUDY ILLES, Session Chair
Professor
Neurology
University of British Columbia
2:15
Panelist Remarks
MARGARET ANDERSON
Chief Operating Officer
FasterCures
SHARON HESTERLEE
Vice President, Translational Research
Muscular Dystrophy Association
TRICIA BROOKS
Managing Director, Alliance Development
Biotechnology Industry Organization
2:55
Respondent Panel Discussion
SUSAN WOLF
McKnight Presidential Professor of Law, Medicine, & Public Policy
University of Minnesota School of Law
RUSTY BROMLEY
Chief Operating Officer
Myelin Repair Foundation
3:05
Discussion with Attendees
JUDY ILLES, Moderator
Professor
Neurology
University of British Columbia
3:20
BREAK
OCR for page 67
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
SESSION V:
COMMUNICATIONS
Session Objective: Explore effective communication strategies that can be used to disseminate information on research and other scientific progress to potential and current funders as well as to constituents, while addressing the challenges of funder and constituent expectations.
Session V
Scenario
The individual from the Colten Foundation is calling again, and has promised that this will be the last time she will call, but she has one last set of very important questions. Based on everything they have already learned from you, their translational research program is making great headway. They are very excited to share the progress with current and potential funders, as well as their constituents. But, she also recognizes the delicate balance that is needed between demonstrating progress and limiting false expectations. Therefore, she is very interested in discussing effective communication strategies that you have used for disseminating information on research and other progress to potential funders and constituents.
3:30
Introduction to the Session
JONATHAN JACOBY, Session Chair
Chief Operating Officer
CollabRx, Inc.
3:35
Panelist Remarks
SHARON TERRY
President and Chief Executive Officer
Genetic Alliance
DAN ZENKA
Vice President, Communications
Prostate Cancer Foundation
OCR for page 68
Venture Philanthropy Strategies to Support Translational Research: Workshop Summary
CATHY CARLSON
Senior Director, Research Information
Research and Clinical Programs Department
National Multiple Sclerosis Society
4:15
Respondent Panel Discussion
SOPHIA COLAMARINO
Vice President, Research
Autism Speaks
RANDALL CARPENTER
Co-Founder, President, and Chief Executive Officer
Seaside Therapeutics
4:25
Discussion with Attendees
JONATHAN JACOBY, Moderator
Chief Operating Officer
CollabRx, Inc.
SESSION VI:
WRAP-UP DISCUSSION
Session Objective: In addition to the areas that have already been discussed, are there additional topics that require exploration? What “next steps” should the IOM’s Neuroscience Forum consider as it moves ahead in this area? How can we capture the innovation and ideas discussed during the meeting to assist you and new colleagues working in these areas?
4:40
Discussion with Attendees
TIMOTHY COETZEE, Chair
Executive Director
Fast Forward of the National Multiple Sclerosis Society
5:00
ADJOURN